tiprankstipranks
Trending News
More News >
Adaptimmune Therapeutics (ADAP)
NASDAQ:ADAP
US Market

Adaptimmune Therapeutics (ADAP) Income Statement

Compare
879 Followers

Adaptimmune Therapeutics Income Statement

Last quarter (Q4 2024), Adaptimmune Therapeutics's total revenue was $3.22M, an increase of 1282.78% from the same quarter last year. In Q4, Adaptimmune Therapeutics's net income was $-74.22M. See Adaptimmune Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 178.03M$ 60.28M$ 27.15M$ 6.15M$ 3.96M
Gross Profit
$ 177.96M$ 50.42M$ -100.58M$ -104.94M$ -87.61M
Operating Expenses
$ 246.72M$ 188.42M$ 191.11M$ 168.40M$ 137.36M
Depreciation and Amortization
$ 11.22M$ 9.84M$ 6.07M$ 6.57M$ 7.65M
EBITDA
$ -52.66M$ -128.20M$ -155.59M$ -155.68M$ -125.81M
Operating Income
$ -68.76M$ -138.04M$ -163.97M$ -162.25M$ -133.41M
Other Income/Expenses
$ 1.52M$ 25.50M$ -1.29M$ 4.95M$ 3.48M
Pretax Income
$ -67.24M$ -112.53M$ -162.96M$ -157.30M$ -129.93M
Net Income
$ -70.81M$ -113.87M$ -165.46M$ -158.09M$ -130.09M
Per Share Metrics
Basic EPS
$ -0.05$ -0.09$ -0.17$ -0.17$ -0.15
Diluted EPS
$ -0.05$ -0.09$ -0.17$ -0.17$ -0.15
Weighted Average Shares Outstanding
1.51B 1.21B 967.24M 934.83M 854.78M
Weighted Average Shares Outstanding (Diluted)
1.51B 1.21B 967.24M 934.83M 854.78M
Currency in USD

Adaptimmune Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis